What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Magnetic resonance imaging
His primary areas of study are Multiple sclerosis, Surgery, Internal medicine, Expanded Disability Status Scale and Glatiramer acetate.
He has researched Multiple sclerosis in several fields, including White matter, Magnetic resonance imaging, Central nervous system disease, Nuclear medicine and Pathology.
His research integrates issues of Interferon beta-1a, Clinical trial and Medical physics in his study of Surgery.
The concepts of his Internal medicine study are interwoven with issues in Placebo, Teriflunomide and Placebo-controlled study.
Jerry S. Wolinsky studies Expanded Disability Status Scale, namely Multiple sclerosis functional composite.
In his study, Chronic cerebrospinal venous insufficiency and Tumefactive multiple sclerosis is inextricably linked to McDonald criteria, which falls within the broad field of Multiple sclerosis functional composite.
His most cited work include:
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria (7085 citations)
- Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis (5753 citations)
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". (4139 citations)
What are the main themes of his work throughout his whole career to date?
Jerry S. Wolinsky mainly focuses on Multiple sclerosis, Internal medicine, Placebo, In patient and Magnetic resonance imaging.
Jerry S. Wolinsky is interested in Expanded Disability Status Scale, which is a field of Multiple sclerosis.
His research in Internal medicine intersects with topics in Teriflunomide, Ocrelizumab and Surgery.
His study in Ocrelizumab is interdisciplinary in nature, drawing from both Relapse rate, Interferon beta-1a and Primary Progressive Multiple Sclerosis.
Jerry S. Wolinsky combines subjects such as Gastroenterology, Clinical endpoint and Adverse effect with his study of Placebo.
The various areas that Jerry S. Wolinsky examines in his Magnetic resonance imaging study include Segmentation, Nuclear magnetic resonance and Atrophy.
He most often published in these fields:
- Multiple sclerosis (52.43%)
- Internal medicine (35.95%)
- Placebo (20.81%)
What were the highlights of his more recent work (between 2016-2021)?
- Multiple sclerosis (52.43%)
- Internal medicine (35.95%)
- Ocrelizumab (14.59%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Multiple sclerosis, Internal medicine, Ocrelizumab, In patient and Placebo.
His research in Multiple sclerosis focuses on subjects like Lesion, which are connected to Fluid-attenuated inversion recovery.
His biological study spans a wide range of topics, including Expanded Disability Status Scale and Oncology.
His Expanded Disability Status Scale study incorporates themes from Confidence interval and Pooled analysis.
His work carried out in the field of Placebo brings together such families of science as Anesthesia, Surgery, Methylprednisolone and Phases of clinical research.
His research investigates the link between Randomized controlled trial and topics such as Glatiramer acetate that cross with problems in Multiple sclerosis functional composite.
Between 2016 and 2021, his most popular works were:
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (720 citations)
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. (670 citations)
- Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis (56 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Magnetic resonance imaging
His primary areas of investigation include Internal medicine, Multiple sclerosis, Ocrelizumab, In patient and Placebo.
His Internal medicine research focuses on Expanded Disability Status Scale and how it relates to Post-hoc analysis.
Jerry S. Wolinsky works in the field of Multiple sclerosis, namely Relapsing remitting.
His Ocrelizumab study combines topics in areas such as Interferon beta-1a and Confidence interval.
He has researched Oncology in several fields, including Interferon, Fingolimod, Glatiramer acetate, Combination therapy and Multiple sclerosis functional composite.
His Hazard ratio research is multidisciplinary, incorporating elements of Siponimod, Surgery, Intention-to-treat analysis, McDonald criteria and Pooled analysis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
